Development of a pharmacokinetic model of mitotane: Toward personalized dosing in adrenocortical carcinoma

Therapeutic Drug Monitoring

Volumn 37, Issue 1, 2015, Pages 58-65

  Kerkhofs, Thomas M A ^a   Derijks, Luc J J ^a   Ettaieb, Hester ^a   Den Hartigh, Jan ^b   Neef, Kees ^c   Gelderblom, Hans ^b   Guchelaar, Henk Jan ^b   Haak, Harm R ^a,c  

^a MÁXIMA MEDICAL CENTER   (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Adrenocortical carcinoma; mitotane; pharmacokinetics

Indexed keywords

MITOTANE;

ADRENAL CORTEX CARCINOMA; ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EXPOSURE; FEMALE; HOSPITAL; HUMAN; LEAN BODY WEIGHT; MALE; PERSONALIZED MEDICINE; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; VOLUME OF DISTRIBUTION AT STEADY-STATE;

EID: 84963941061     PISSN: 01634356     EISSN: 15363694     Source Type: Journal    
DOI: 10.1097/FTD.0000000000000102     Document Type: Article

References (22)

1. Fassnacht M, Allolio B. Clinical management of adrenocortical carcinoma. Best Pract Res Clin Endocrinol Metab. 2009;23:273-289.
2. Baudin E, Leboulleux S, Al Ghuzlan A, et al. Therapeutic management of advanced adrenocortical carcinoma: what do we know in 2011? Horm Cancer. 2011;2:363-371.
3. Fassnacht M, Terzolo M, Allolio B, et al. Combination chemotherapy in advanced adrenocortical carcinoma. N Engl J Med. 2012;366:2189-2197.
4. Terzolo M, Angeli A, Fassnacht M, et al. Adjuvant mitotane treatment for adrenocortical carcinoma. N Engl J Med. 2007;356:2372-2380.
5. Berruti A, Baudin E, Gelderblom H, et al. Adrenal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2012;23:vii131-vii138.
6. Hahner S, Fassnacht M. Mitotane for adrenocortical carcinoma treatment. Curr Opin Investig Drugs. 2005;6:386-394.
7. Haak HR, Hermans J, van de Velde CJ, et al. Optimal treatment of adrenocortical carcinoma with mitotane: results in a consecutive series of 96 patients. Br J Cancer. 1994;69:947-951.
8. Baudin E, Pellegriti G, Bonnay M, et al. Impact of monitoring plasma 1,1-dichlorodiphenyldichloroethane (o,p'DDD) levels on the treatment of patients with adrenocortical carcinoma. Cancer. 2001;92:1385-1392.
9. van Slooten H, Moolenaar AJ, van Seters AP, et al. The treatment of adrenocortical carcinoma with o,p'-DDD: prognostic implications of serum level monitoring. Eur J Cancer Clin Oncol. 1984;20:47-53.
10. Faggiano A, Leboulleux S, Young J, et al. Rapidly progressing high o, p'DDD doses shorten the time required to reach the therapeutic threshold with an acceptable tolerance: preliminary results. Clin Endocrinol (Oxf). 2006;64:110-113.
11. Terzolo M, Pia A, Berruti A, et al. Low-dose monitored mitotane treatment achieves the therapeutic range with manageable side effects in patients with adrenocortical cancer. J Clin Endocrinol Metab. 2000;85:2234-2238.
12. Kerkhofs T, Baudin E, Terzolo M, et al. Comparison of two mitotane starting dose regimens in patients with advanced adrenocortical carcinoma. J Clin Endocrinol Metab. 2013;98:4759-4767.
13. D'Avolio A, De Francia S, Basile V, et al. Influence of the CYP2B6 polymorphism on the pharmacokinetics of mitotane. Pharmacogenet Genomics. 2013;23:293-300.
14. von Slooten H, van Seters AP, Smeenk D, et al. O,p'-DDD (mitotane) levels in plasma and tissues during chemotherapy and at autopsy. Cancer Chemother Pharmacol. 1982;9:85-88.
15. Hermsen IG, den Hartigh J, Haak HR. Mitotane serum level analysis; good agreement between two different assays. Clin Endocrinol (Oxf). 2010;73:271-272.
16. Proost JH, Meijer DK. MW/Pharm, an integrated software package for drug dosage regimen calculation and therapeutic drug monitoring. Comput Biol Med. 1992;22:155-163.
17. Proost JH, Eleveld DJ. Performance of an iterative two-stage bayesian technique for population pharmacokinetic analysis of rich data sets. Pharm Res. 2006;23:2748-2759.
18. Proost JH, Schiere S, Eleveld DJ, et al. Simultaneous versus sequential pharmacokinetic-pharmacodynamic population analysis using an iterative two-stage Bayesian technique. Biopharm Drug Dispos. 2007;28: 455-473.
19. Moy RH. Studies of the pharmacology of o,p'DDD in man. J Lab Clin Med. 1961;58:296-304.
20. Chennavasin P, Brater DC. Aminoglycoside dosage adjustment in renal failure: a hand-held calculator program. Eur J Clin Pharmacol. 1982;22:91-94.
21. Du Bois D, Du Bois EF. A formula to estimate the approximate surface area if height and weight be known. 1916. Nutrition. 1989;5:303-311; discussion 312-313.
22. Mauclere-Denost S, Leboulleux S, Borget I, et al. High-dose mitotane strategy in adrenocortical carcinoma: prospective analysis of plasma mitotane measurement during the first 3 months of follow-up. Eur J Endocrinol. 2012;166:261-268.